Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
‘Real momentum’ or ‘absurd’? Trump stance shakes up psychedelics
The Trump administration's support could launch psychedelics across the regulatory finish line or doom the field to perpetual questions of legitimacy.
Darren Incorvaia
May 4, 2026 3:30am
UCB inks $2B Candid buyout to join Gilead in autoimmune field
May 4, 2026 7:46am
Takeda drug improves convenience for PID patients in pivotal trial
May 4, 2026 10:48am
Mirum maps FDA path after anti-itch candidate scores ph. 2 win
May 4, 2026 10:40am
Windward breezes toward phase 3 with $165M for TSLP ambitions
May 4, 2026 10:31am
Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 study
May 4, 2026 8:06am
More News
Seaport CEO's 'rationale behind going public' via $255M IPO
May 1, 2026 12:30pm
Fierce Pharma
Summit shares tumble on interim PD-1/VEGF trial miss
May 1, 2026 10:56am
CBER chief Prasad steps aside, deputy takes the reins
May 1, 2026 9:58am
Ligand tries to disembark from Viking pact, alleging breach
May 1, 2026 8:31am
See more stories